CXCL10 rs8878 identifies a genotype-associated immune phenotype linked to T-lymphocyte preservation and survival in sepsis - Scorecard - MDSpire

CXCL10 rs8878 as a Genetic Marker for Immune Phenotypes Associated with T-Lymphocyte Maintenance and Survival in Sepsis

  • By

  • Birte Dyck

  • Andrea Witowski

  • Thilo Bracht

  • Malte Bayer

  • Patrick Thon

  • Dominik Ziehe

  • Tim Rahmel

  • Matthias Unterberg

  • Britta Westhus

  • Lars Palmowski

  • Hartmuth Nowak

  • Stefan Felix Ehrentraut

  • Jennifer Orlowski

  • Alexander von Busch

  • Alexander Zarbock

  • Nina Babel

  • Moritz Anft

  • Dietrich Henzler

  • Michael Adamzik

  • Lars Bergmann

  • Barbara Sitek

  • Björn Koos

  • Katharina Rump

  • July 17, 2026

Share

Clinical Scorecard: CXCL10 rs8878 as a Genetic Marker for Immune Phenotypes Associated with T-Lymphocyte Maintenance and Survival in Sepsis

At a Glance

CategoryDetail
ConditionSepsis
Key MechanismsDysregulated host response to infection, alterations in T lymphocyte homeostasis, and CXCL10-mediated immune activation.
Target PopulationSeptic patients (n=278)
Care SettingProspective cohort study

Key Highlights

  • CXCL10 rs8878 genotype associated with T cell dysregulation.
  • AA genotype carriers showed higher T cell counts and improved survival.
  • Increased CXCL10 mRNA expression in non-survivors indicates genotype-dependent regulation.
  • CXCL10 concentrations correlated with inflammatory cytokines and T cell counts.
  • Findings suggest CXCL10 as a potential biomarker for risk stratification in sepsis.

Guideline-Based Recommendations

Diagnosis

  • Assess CXCL10 genotype for understanding immune response in sepsis.

Management

  • Consider CXCL10 as a candidate target for immunomodulatory therapies.

Monitoring & Follow-up

  • Monitor circulating T cell counts and CXCL10 levels in septic patients.

Risks

  • Higher CXCL10 levels may contribute to T cell exhaustion and apoptosis.

Patient & Prescribing Data

Septic patients with varying CXCL10 genotypes.

Genotype-dependent modulation of adaptive immune response may inform treatment strategies.

Clinical Best Practices

  • Evaluate genetic variations in CXCL10 for personalized patient management.
  • Incorporate immune monitoring in the management of sepsis.

Related Resources & Content

Original Source(s)

CXCL10 rs8878 identifies a genotype-associated immune phenotype linked to T-lymphocyte preservation and survival in sepsis

  • by Birte Dyck, Andrea Witowski, Thilo Bracht, Malte Bayer, Patrick Thon, Dominik Ziehe, Tim Rahmel, Matthias Unterberg, Britta Westhus, Lars Palmowski, Hartmuth Nowak, Stefan Felix Ehrentraut, Jennifer Orlowski, Alexander von Busch, Alexander Zarbock, Nina Babel, Moritz Anft, Dietrich Henzler, Michael Adamzik, Lars Bergmann, Barbara Sitek, Björn Koos, Katharina Rump

  • July 17, 2026

Related Content

Interpretable gradient boosting machine model for predicting in-hospital mortality in sepsis-induced myocardial injury: a multicenter development, validation, and web-based clinical implementation

In reply to; beyond shear stress: septic microvascular failure remains a multifactorial phenomenon

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.